AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02435303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04131283
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasoconstrictor solution is applied on the surface of the attached gingiva and on the gingival sulcus.
Trial: NCT01581177
Drug: Placebo DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo DPI with 0 mcg Albuterol/inhalation
Trial: NCT02897050
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1200mg/m2/d, po, d1-d21
Trial: NCT02897050
Drug: Cyclophosphamide (tablet)
RxNorm normalized name: cyclophosphamide Oral Tablet
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 50 mg/d, po, d1-d21
Trial: NCT02897050
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil 500mg/m2, iv, d1
Trial: NCT02897050
Drug: Cyclophosphamide (injection)
RxNorm normalized name: cyclophosphamide Injection
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 500mg/m2, iv, d1
Trial: NCT01396889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months
Trial: NCT00362245
Drug: Systemic and Intra-Thecal Amikacin Therapy
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02541864
Drug: Hybrid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
Trial: NCT01526564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 t.i.d, two plates per time
Trial: NCT01531673
Drug: Placebo matched to VX-661
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02084563
Drug: Induction Chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy for patients with AML eligible for intensive chemotherapy:~* Cytarabine 200 mg/m2 IV continuous infusion days 1-7~* Daunorubicin 90 mg/m2 intravenous piggyback days 1-3
Trial: NCT02084563
Drug: Consolidation Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemotherapy for patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~-Cytarabine 1.5 g/m2 IV in 3 hours days 1, 3 and 5 for 3 cycles
Trial: NCT04196491
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lymphodepleting Chemotherapy
Trial: NCT02389452
Drug: Synvisc-One
RxNorm normalized name: Synvisc-One 48mg/6ml Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intraarticular injection
Trial: NCT00954265
Drug: 250 mcg recombinant HCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ovulation triggering
Trial: NCT03790852
Drug: KSI-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection
Trial: NCT05264493
Drug: NaxRedy ™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg (5 mg/0.5 mL) IM autoinjector injection into lateral thigh
Trial: NCT00414908
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00727935
Drug: Ropivacaïne
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00727935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00564590
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg of Melatonin once a day for 3 months
Trial: NCT00564590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once a day
Trial: NCT02522975
Drug: EPIAO®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Trial: NCT02522975
Drug: EPREX®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic /anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Trial: NCT03742986
Drug: Doxorubicin 60mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m\^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)
Trial: NCT03742986
Drug: Cyclophosphamide 600mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 600mg/m\^2 on Day 1 of every 14 day cycle (Cycle 5-8)
Trial: NCT02385617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
Trial: NCT04565756
Drug: EXN407
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EXN407 or placebo will be administered as a single 30 microliters drop twice a day, by unilateral eye drop administration to the study eye only.
Trial: NCT03066830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT03066830
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT03799679
Drug: Chemotherapeutic Agent
RxNorm normalized name: Other chemotherapeutics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1. Patients will receive this as a single-agent for the first twelve weeks, then followed by epirubicin in combination with cyclophosphamide.~Drug: Epirubicin 90 mg/m² given IV~Drug: Cyclophosphamide 600 mg/m² given IV
Trial: NCT04425993
Drug: Indomethacin 100 MG
RxNorm normalized name: indomethacin 100 MG
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.
Trial: NCT04425993
Drug: Sublingual Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients without contraindications should receive sublingual placebo within 5 minutes before ERCP.
Trial: NCT04425993
Drug: Rectal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients without contraindications should receive rectal placebo within 30 min before ERCP.
Trial: NCT00152113
Drug: See intervention description
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea and azathioprine were administered for a 3 month period prior to the initiation of the transplant procedure in an effort to help prevent rejection of the donor product. Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3. MMF was administered for GVHD prophylaxis. Two separate infusions of donor stem cells were administered with fixed doses of CD3 and CD34 cells. These haploidentical stem cells were processed using the investigational CliniMACS device.
Trial: NCT02635282
Drug: intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02881177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU
Trial: NCT04420689
Drug: ALM-488
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALM-488 Sterile Solution is an intravenously administered, synthetic, peptide dye conjugate indicated for the real-time intraoperative fluorescence detection and localization of nerve tissue.
Trial: NCT00753675
Drug: Placebo matching ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ZD6474 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Trial: NCT02141191
Drug: inhaled hypertonic saline (7%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled hypertonic saline delivered by nasal cannula using the Parion transnasal Pulmonary Aerosol Delivery (tPAD) device
Trial: NCT01720316
Drug: Glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-blind placebo controlled trial of glycine or placebo, followed by open-label glycine
Trial: NCT01720316
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00713271
Drug: AZD3199
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose~Dry powder for inhalation, o.d., 1+12 days
Trial: NCT00713271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00713271
Drug: AZD3199
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intermediate dose~Dry powder for inhalation, o.d., 1+12 days
Trial: NCT00713271
Drug: AZD3199
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high dose~Dry powder for inhalation, o.d., 1+12 days
Trial: NCT03568578
Drug: Anluohuaxian Pill 12g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will be given Entecavir 0.5 mg and Anluohuaxian Pill 12g a day for 2 years
Trial: NCT03669601
Drug: AZD6738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.
Trial: NCT00080353
Drug: rF-go 100P209
RxNorm normalized name: Go-dry
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00036283
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00369343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, daily (QD), tablet form, treatment period up to 8 weeks
Trial: NCT04001803
Drug: CAB LA+RPV LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one tablet of CAB 30 milligram(mg) + RPV 25 mg once daily from Day 1 for 1 month. During month 1, subjects will receive 600 mg of CAB LA injection+ 900 mg of RPV LA injection. Following Month 1, subjects will receive 400mg of CAB LA + 600mg of RPV LA at each subsequent injection.
Trial: NCT04014218
Drug: Inhalation Sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Sedation by Administration of Sevoflurane
Trial: NCT04014218
Drug: Intravenous Sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Sedation by Administration of Propofol
Trial: NCT00461825
Drug: Group A: CsA + Azathioprine(1 to 2 mg/kg/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00461825
Drug: Group B: CsA + CellCept(500 mg x 2/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00461825
Drug: Group C: CsAm
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02021214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02539017
Drug: Chemo
RxNorm normalized name: Chemolock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles
Trial: NCT03159832
Drug: SHR3824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects were given SHR3824 20mg only one time.
Trial: NCT01945944
Drug: Hypertonic saline (3%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mL of HTS given via nebulizer every 6hrs
Trial: NCT00526318
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00526318
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01776970
Drug: Cannabis Sativa extract Oromucosal spray
RxNorm normalized name: Cannabis sativa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo
Trial: NCT03573037
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:1 randomization to 1-month anticoagulation or 2-month anticoagulation after radiofrequency catheter ablation of paroxismal atrial fibrillation
Trial: NCT03912740
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both groups will have remifentanil analgesia guided by the Nol-Index
Trial: NCT00508911
Drug: GW876008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW876008 tablets will be available as white to off-white coated tablets. Each subject will receive a single oral dose of GW876008, daily for up to 35 days in Session 2. GW876008 will be administered in the morning with a light breakfast.
Trial: NCT02735577
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.
Trial: NCT00039390
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally (PO)
Trial: NCT03704675
Drug: TEW-7197
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00490971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily until recurrence (only after initial 15 weeks on paliperidone ER)
Trial: NCT04500249
Drug: infiltration rescue intraoperative analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in the case of intraoperative pain perception, rescue infiltration analgesia using 1 % lidocaine administered by the operator into the operation field.
Trial: NCT04500249
Drug: rescue antyhypertensive medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in the case of intraoperative hypertension reluctant to rescue analgesia, rescue intravenous antihypertensive medication using 10 mcg of urapidil will be administered by anaesthesiologist
Trial: NCT04500249
Drug: rescue antyemetic medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in the case of postoperative nausea and vomitting, rescue intravenous antiemetic medication using 4 mg of ondansetron will be administered by anaesthesiologist
Trial: NCT04500249
Drug: rescue antyhypotensive medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in the case of intraoperative hypotension, rescue intravenous antihypotensive medication using 10 mg of ephedrine will be administered by anaesthesiologist
Trial: NCT04500249
Drug: rescue antyhypotensive medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in the case of intraoperative bradycardia, rescue intravenous antihypotensive medication using 500 mcg of atropine will be administered by anaesthesiologist
Trial: NCT01628562
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.5 mcg/kg/min
Trial: NCT02789969
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 1.5mcg/kg IV
Trial: NCT01775423
Drug: BBI608
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02007720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT02440061
Drug: Synthetic human AG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic human AG (0.28 μg/kg) bolus over 1 minute followed by 2 μg/kg/hr continuous infusion for 4.5 hours.
Trial: NCT02440061
Drug: Arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine hydrochloride (5 g) intravenously over 45 seconds.
Trial: NCT02440061
Drug: 0.9% saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A continuous infusion of 0.9% saline solution (control) for 4.5 hours.
Trial: NCT02590900
Drug: intravenous paracetamol (acetaminophen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paracetamol disposition in young women, exploring the impact of covariates (pregnancy, postpartum, oral contraceptives) in this population.
Trial: NCT00957177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02021461
Drug: ESL Tutti-Frutti taste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension with Tutti-Frutti flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
Trial: NCT00250172
Drug: [C-11](R)-rolipram
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02898077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02703181
Drug: Placebo to match GSK557296
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to off-white 0.270 inches x 0.700 inches oblong film coated Tablet containing placebo. To be swallowed whole with water, not to be chewed.
Trial: NCT01419535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.
Trial: NCT01461733
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo delivered blinded
Trial: NCT02939209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients may be randomized to placebo.
Trial: NCT02240459
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes
Trial: NCT02876796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule(s) administered orally
Trial: NCT02823470
Drug: LUM/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
Trial: NCT01194375
Drug: Low Strength IDP-107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day for 16 weeks
Trial: NCT01194375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day for 16 weeks
Trial: NCT00027547
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00841217
Drug: GW501516
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mg/day
Trial: NCT00841217
Drug: placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01278602
Drug: R-ESHAP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
Trial: NCT03450759
Drug: AZD9977 Oral suspension (reference)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized subjects will receive single oral dose of AZD9977 oral suspension 15 mg/mL on Days 1, 3, 5 and 7 in Part A.
Trial: NCT03450759
Drug: AZD9977 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized subjects will receive single oral dose of AZD9977 capsule 65 mg on Days 1, 3, 5 and 7 in Part A.
Trial: NCT03450759
Drug: AZD9977 ER capsule (Int. rate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized subjects will receive single oral dose of AZD9977 ER capsule (Int rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
Trial: NCT01223404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are administered a placebo patch and a placebo capsule
Trial: NCT04999618
Drug: Haemoblock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivering with transdermal patches